Lead Sponsor

Pfizer

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•The patient must have or be suspected of having a ventilator-associated pneumonia (VAP) due to MRSA.
•Patient must be hospitalized for at least 5 days, must be ventilator-dependent ≥ 48 hours prior to screen/baseline, and anticipated to remain on the ventilator for 72 hours after enrollment so follow-up BAL can be performed.
•Clinical picture compatible with pneumonia (acquired during ventilation)
•Chest X Ray at baseline/screen or within 24 hours of initiation of therapy must be consistent with diagnosis of pneumonia

•Hypersensitivity to linezolid, vancomycin, or one of the excipients in any of these drug formulations.
•Infections due to gram-positive organisms known to be resistant to either of the study drugs.
•Any antibiotic used in the treatment of MRSA, such as vancomycin, TMP/SMX, rifampin, or linezolid, for more than 48 hours prior to patient's enrollment into the study.
•Patients with neutropenia, AIDS, lymphoma or anticipated chemotherapy.
•Patients who have long-term tracheostomy (for more than 60 days). Acute tracheostomy patients are allowed.

Related studies

NCT07052604 · Pneumonia, Ventilator-Associated, Stenotrophomonas Maltophilia, and more

NCT05117125 · Pneumonia, Ventilator-Associated

NCT05405491 · Pneumonia, Ventilator-Associated, Pneumonia, Hospital-Acquired, and more

NCT06848010 · Pneumonia, Ventilator-Associated, Mechanical Ventilation

NCT07350122 · Cardiac Surgical Procedures (Postoperative Population), Critical Illness, and more

Microbiologic Response With Linezolid And Vancomycin In Ventilator-Associated Pneumonia Due To Methicillin Resistant Staphylococcus Aureus